ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Phase 3
Recruiting
- Conditions
- Immunoglobulin A NephropathyIgAN
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06291376
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Adult Participants
- Interventions
- Drug: Gefurulimab AI
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT06208488
- Locations
- 🇨🇦
Research Site, Laval, Quebec, Canada
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Phase 3
Recruiting
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06183931
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06173596
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06160414
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Phase 3
Active, not recruiting
- Conditions
- Hypophosphatasia
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06079372
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06079281
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06079359
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06071442
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
Phase 4
Not yet recruiting
- Conditions
- Hypophosphatasia
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06015750
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath